TYME - Tyme Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5600
-0.0900 (-5.45%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.6500
Open1.7000
Bid1.5600 x 800
Ask1.5800 x 800
Day's Range1.5000 - 1.7000
52 Week Range0.9200 - 3.4200
Volume598,815
Avg. Volume513,930
Market Cap175.553M
Beta (5Y Monthly)0.40
PE Ratio (TTM)N/A
EPS (TTM)-0.2650
Earnings DateNov 03, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
  • GlobeNewswire

    TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the first sarcoma cancer patient has been dosed at the Sarcoma Oncology Center in the HopES Phase II trial designed to evaluate SM-88 (racemetyrosine) for the treatment of high-risk sarcomas, which are ultra-rare cancers with high unmet medical need. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells’ protein synthesis, leading to a breakdown of the cancer’s key defenses and cell death.

  • Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study
    Zacks

    Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study

    Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.

  • Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up
    Zacks

    Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up

    Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.

  • GlobeNewswire

    TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic Pancreatic Cancer

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal trial designed to support approval of SM-88 (racemetyrosine) for the third-line treatment of patients with metastatic pancreatic cancer. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells’ protein synthesis, leading to a breakdown of the cancer’s key defenses and cell death.

  • MarketWatch

    Tyme stock rises on Eage collaboration for cancer drug

    Shares of Tyme Technologies were up 23% in premarket trading on Tuesday after the biotechnology company said it had formed a collaboration with Eagle Pharmaceuticals Inc. to co-promote Tyme's investigational cancer treatment. Eagle's stock gained 3% before the market opened. Per the terms of the agreement, Tyme will receive $20 million upfront and an additional $20 million in milestone payments if certain endpoints are met. If the therapy, oral SM-88, is approved, Eagle is responsible for one-fourth of sales efforts and is expected to receive 15% of net revenue. The treatment has completed mid-stage trials. Tyme's stock has fallen 54% over the last year; Eagle's stock is up 40%. The S&P 500 has gained about 28% over the last 52 weeks.

  • Business Wire

    Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer

    Tyme Technologies, Inc. (Nasdaq: TYME) ("TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), and Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle"), today announced the formation of a U.S. strategic collaboration focused on the co-promotion of TYME’s lead CMBT candidate oral SM-88 in advanced cancers. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells’ protein synthesis, leading to a breakdown of the cancer’s key defenses and cell death. In clinical trials, oral SM-88 has demonstrated complete or partial responses across 15 different cancers, including pancreatic, prostate, sarcoma, breast, lung, and blood cancers with minimal serious grade 3 or higher adverse events.

  • Analysts: These 3 “Strong Buy” Penny Stocks Could Soar in 2020
    TipRanks

    Analysts: These 3 “Strong Buy” Penny Stocks Could Soar in 2020

    Penny stocks offer a conundrum for the investor; The low valuation scares the cautiously inclined away due to the cheap nature of the stock. On the other hand, they represent incredible opportunity for the risk tolerant amongst us. Invariably, this almost "catch 22" like situation begs the question: why are these companies priced so low? Is it due to bad fundamentals, indicating stocks that aren’t worth pursuing? Or is it that the market is missing something and there is opportunity to pick up a winner at a ridiculously low price?A bit of both, possibly. There is no doubt, though, that while a penny stock might represent the road to majestic returns, it is also inherently riskier, increasing the possibility of losing your hard-earned cash.So, how to find which are the penny stocks to invest in, then? TipRanks’ Stock Screener comes in handy here. The tool identified for us three micro-cap stocks that have taken a beating in the past year, but which the people in the know think are ready for some upside action in 2020. Additionally, all three currently have a Strong Buy consensus rating. Let’s check them out.KushCo Holdings (KSHB)KushCo sells ancillary goods & services to the global cannabis industry, mostly vaping related products. The cannabis industry as a whole has had a torrid 2019; The industry has struggled on various fronts, including supply problems and regulatory issues.The company, in this instance, is even further exposed, as vaping related “mystery lung” illnesses and even deaths have surfaced this year, raising the alarm bells on the safety of vaping products. Since then, the reason for the illnesses has been identified as vitamin E acetate found in less rigorously tested vaping products which are sold on the black market.While the industry is not completely out of the woods just yet, eventually, in a market still finding its feet, the companies with strong fundamentals are likely to kick off the dust and rise again. Jefferies’ Owen Bennett believes KSHB is one such company. The analyst said, “Despite an attractive sales profile vs NA cannabis peers, operating in a federally legal way in the US (can be national/list on a major exchange), and with strong barriers to entry, it's valuation is one of the cheapest. With current multiple headwinds set to unwind (particularly on vapour), and additional positive catalysts likely, we see significant re-rating potential the next 12-24 months.”To this end, Bennett rates KushCo shares a Buy along with a $3 price target, which represents over 130% upside potential. (To watch Bennett’s track record, click here)Does the Street reckon the cannabis product manufacturer will blow the smoke away to rise again? Yes, it does. A Strong Buy analyst consensus rating breaks down into 4 Buy ratings with no Holds or Sells. The average price target of $4.33, even outstrips Bennet’s bullish thesis, and indicates high upside potential of 203%. (See KushCo price targets and analyst ratings on TipRanks)Sesen Bio (SESN)Sesen Bio shareholders have had a rough 2019, as Mr. Market chopped off nearly 30% of the company’s stock price. However, 5-star Canaccord analyst John Newman thinks this new, lower stock price could offer new investors an opportunity to get into SESN on the cheap. The analyst reiterated a Buy rating on Sesen, alongside a price target of $5, implying potential upside of a blockbusting 405%. (To watch Newman’s track record, click here)Sesen’s modus operandi is the fight against cancer with the development of fusion protein medicines. The biotech’s lead candidate is Vicinium, a treatment for bladder cancer. The drug is currently in a Phase 3 trial, and Sesen recently initiated its Biologics License Application (BLA) for Vicinium with the FDA. Once the company receives acknowledgement of the BLA, it will begin planning ahead for its ODAC (Oncology Drugs Advisory Committee), currently expected to take place in 2020.With the confirmatory study for Vicinium in its sight, Newman believes there is “opportunity for label expansion.” The top analyst said, “We believe Sesen's confirmatory trial could show superiority vs control in NMIBC (non-muscle invasive bladder cancer), boosting usage among urologists and strengthening reimbursement from insurers. In addition, expanding to inadequate BCG dosed patients should broaden the market opportunity from BCG-intolerant patients, a potential positive… We continue to expect the ODAC for Vicinium to be positive, especially in light of a continued BCG (Bacilus Calmette Guérin) shortage, and believe the panel will vote in favor of Vicinium's favorable benefit/risk profile.”Two other analysts have chipped in with a view on the biotech’s prospects over the last 3 months. All are vocal in their support and rate the stock a Buy. Therefore, Sesen has a Strong Buy consensus rating. The average price target is $3.42 and indicates possible huge gains of 227% in the coming year. (See Sesen stock-price forecast on TipRanks)Tyme Technologies (TYME)Time hasn’t been kind to biotech Tyme Technologies; 2019 has continued a multi-year trend and has been a bit of a letdown, to say the least. Since the turn of the year this beaten down stock has shed more than 70% of its value. That, according to some optimistic analysts, could be about to change.Tyme is a fellow company focused on cancer cures. Its lead candidate is SM-88, currently in Phase 2 development for pancreatic and prostate cancer. Earlier this year, Tyme presented encouraging data from the trial at ESMO (european society for medical oncology) and Evercore’s Joshua Schimmer has been assessing the results.The 5-star analyst believes that “significant unmet need remains in pancreatic cancer.” He said, “Aggregate 5-year survival rate for metastatic pancreatic cancer is only 9%, and recent oncology advancements have failed to be effective in this tumor. We estimated a market size for 3L alone of >$500M, and penetration into earlier lines of therapy would broaden peak sales… While obviously not without risk, especially in pancreatic cancer, SM-88 has shown broad anti-tumor activity in early clinical studies, physician feedback has been strong, and upside should the product succeed is substantial.”Accordingly, Schimmer reiterated an Outperform rating on Tyme, alongside a price target of $7. Should the target be met, investors could be lining pockets with an incredible 566% gain over the next 12 months. (To watch Schimmer’s track record, click here)The Street is rather quiet right now, in regard to Tyme’s prospects. Only two other analysts have recently thrown the hat in with a view on the biotech, both giving it the thumbs up. Tyme’s Strong Buy consensus rating comes with an average price target of $8.50. which implies incredible upside of 721%. (See Tyme price targets and analyst ratings on TipRanks)

  • Hedge Funds Have Never Been More Bullish On Tyme Technologies, Inc. (TYME)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Tyme Technologies, Inc. (TYME)

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]

  • Wall Street Suggests These Falling Knives
    GuruFocus.com

    Wall Street Suggests These Falling Knives

    They have a low financial burden ,which decreases bankruptcy risk Continue reading...

  • GlobeNewswire

    Tyme Technologies to Present at the 2019 Cross-Border Healthcare Winter Summit in New York

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 2019 Cross-Border Healthcare Winter Summit on Tuesday, December 10, 2019. The Company will present its corporate overview for 2019 with a special focus on growth opportunities driven by advances in the science of cancer metabolism, recently launched pivotal trial in pancreatic cancer and expanding clinical plans for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate, sarcoma, breast and hematological cancers. Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.

  • GlobeNewswire

    TYME to Ring Nasdaq Opening Bell on November 27 to Honor All Stakeholders Committed to Finding a Cure for Patients with Pancreatic Cancer

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced it will ring the Nasdaq Opening Bell on Wednesday, November 27, to honor the many stakeholders who are committed to finding a cure for patients with pancreatic cancer during Pancreatic Cancer Awareness Month. TYME will be joined by employees, oncologists, researchers and representatives of leading patient advocacy organizations for pancreatic cancer, namely the Pancreatic Cancer Action Network (PanCAN) and the Lustgarten Foundation.

  • GlobeNewswire

    Tyme Technologies to Present at the Evercore ISI HealthCONx Conference 2019

    NEW YORK, Nov. 21, 2019 -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that.

  • GlobeNewswire

    Tyme Technologies to Present at Jefferies 2019 London Healthcare Conference on November 20-21, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Jefferies 2019 London Healthcare Conference on Wednesday and Thursday, November 20 and 21, 2019. In one-on-one sessions, the Company will present its corporate overview for 2019 with a special focus on growth opportunities driven by advances in its science of cancer metabolism and clinical and regulatory developments for its lead candidate SM-88 (racemetyrosine) in metastatic cancers. Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.

  • GlobeNewswire

    TYME Presents Business Update and Reports Second Quarter Fiscal 2020 Financial and Operating Results

    Quarterly conference call today, November 4th, at 5 p.m. Eastern TimeUpdated Data From TYME-88-Panc PET Imaging and TYME-18 Preclinical Studies on Conference CallExpect.

  • GlobeNewswire

    TYME Presents Business Update and Announces Second Quarter Fiscal 2020 Conference Call and Preliminary Operational Results

    TYME Launched the Pivotal Stage of TYME-88-PANC Trial to Evaluate Oral SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic CancerTYME Presented Final Data at.

  • Lilly's Pancreatic Cancer Candidate Fails in Phase III Study
    Zacks

    Lilly's Pancreatic Cancer Candidate Fails in Phase III Study

    Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.

  • How Much Are Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Taking Off The Table?
    Simply Wall St.

    How Much Are Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Taking Off The Table?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • GlobeNewswire

    TYME Presented Updated Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer

    Study results demonstrate that oral SM-88 may play a clinically meaningful role in postponing use of hormonal castration in prostate cancer patients with rising.

  • GlobeNewswire

    TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer

    Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that its open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging overall (OS) results and has a well-tolerated safety profile. TYME also announced encouraging Quality of Life data for this challenging patient population.

  • Tyme Initiates Pivotal Stage of Pancreatic Cancer Study
    Zacks

    Tyme Initiates Pivotal Stage of Pancreatic Cancer Study

    Tyme (TYME) initiates the pivotal stage of the TYME-88-Panc study evaluating oral SM-88 (racemetyrosine) for third-line treatment of patients with metastatic pancreatic cancer.

  • GlobeNewswire

    TYME Launches Pivotal Stage of TYME-88-PANC Trial to Evaluate SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic Cancer

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the start of the pivotal stage of the TYME-88-Panc trial to evaluate the clinical benefits of its lead CMBT candidate, oral SM-88 (racemetyrosine), for third-line treatment of patients with metastatic pancreatic cancer. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells’ protein synthesis, leading to a breakdown of the cancer’s key defenses and cell death.

  • GlobeNewswire

    Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019. The Company will present its corporate overview for 2019 with a special focus on growth opportunities driven by advancements in the science of cancer metabolism and clinical developments for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate, and sarcoma cancers. A live webcast of the presentation will be accessible on the events page under the Investor Relations section of Tyme Technologies’ website at www.tymeinc.com.

  • Will Tyme Technologies Continue to Surge Higher?
    Zacks

    Will Tyme Technologies Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Tyme Technologies.

  • GlobeNewswire

    TYME Presents Positive Circulating Tumor Cell Data from TYME-88-Panc Study in Patients with Advanced Pancreatic Cancer at AACR PANC 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), reported encouraging data on circulating tumor cells (CTCs) and a correlation with decrease in risk of death using TYME's lead candidate, oral SM-88 (racemetyrosine), in patients with metastatic pancreatic cancer. The data were presented at the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, taking place September 6-9, 2019, at the Westin Copley Place in Boston, Massachusetts.

  • GlobeNewswire

    Tyme Technologies to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright on September 9, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright in New York City on Monday, September 9, 2019. The Company will present its corporate overview for 2019 with special focus on growth opportunities driven by advances in the science of cancer metabolism and clinical developments for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers.